S. Mok

R. Berkowitz, S. Mok, M. Muto, 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.

R. Berkowitz, S. Mok, W. Welch, 2000, Gynecologic oncology.

Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

R. Berkowitz, S. Mok, K. Wong, 2006, Neoplasia.

A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.

J. Niloff, D. Cramer, S. Mok, 1999, Obstetrics and gynecology.

Inhibition of Dab2 Expression with Antisense Oligodeoxynucleotides in Mouse Embryos

S. Mok, W. Chan, K. Cheung, 2008, Neuroembryology and Aging.

Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes

M. Lawrence, R. Berkowitz, A. Nag, 2021, Cancers.

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines

S. Mok, S. Ho, K. Lau, 2000, Molecular carcinogenesis.

The Monkey, the Hen, and the Mouse: Models to Advance Ovarian Cancer Chemoprevention

S. Mok, K. Lu, M. Yates, 2009, Cancer Prevention Research.

BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum

R. Berkowitz, S. Mok, M. Muto, 1998, Obstetrics and gynecology.

Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer.

Dale Edwards, D. Cramer, B. Ye, 2008, Cancer research.

Phospho-EGFR / Src / FAK / Paxillin in Ovarian Cancer Pleiotropic Effects on Tyrosine Activation of Platelet-Activating Factor Receptor and Updated

Dale Edwards, D. Cramer, B. Ye, 2008 .

SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.

S. Mok, D. Fulton, N. Said, 2007, Neoplasia.

Regulation of aromatase expression in human ovarian surface epithelial cells.

S. Mok, S. Chen, T. Okubo, 2000, The Journal of clinical endocrinology and metabolism.

Osteopontin is down-regulated in hydatidiform mole.

R. Berkowitz, S. Mok, Jae-Hoon Kim, 2003, Gynecologic oncology.

Deep learning on image-omics data in identifying prognostic immune biomarkers for ovarian cancer

Stephen T. C. Wong, A. Jazaeri, J. Sheng, 2020 .

Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.

Prahlad T. Ram, P. Ram, A. Sood, 2016, Cell metabolism.

A Glucose G 6 P F 6 P GAP DHAP 3 PG Pyruvate Acetyl-CoA Citrate α-ketoglutarate Succinate Fumarate Malate OAA Aspartate Glutamate Glutamine PPP pathway Lactate

Prahlad T. Ram, P. Ram, A. Sood, 2016 .

p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.

R. Berkowitz, S. Mok, D. Genest, 1998, The Journal of reproductive medicine.

Etiology and Pathogenesis of Epithelial Ovarian Cancer

R. Berkowitz, M. Birrer, S. Mok, 2007, Disease markers.

ResearchActivated networking of platelet activating factor receptor and FAK / STAT 1 induces malignant potential in BRCA 1-mutant at-risk ovarian epithelium

W. Qiu, Dale Edwards, D. Cramer, 2015 .

Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium

W. Qiu, Dale Edwards, D. Cramer, 2010, Reproductive biology and endocrinology : RB&E.

Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer.

R. Berkowitz, D. Cramer, S. Mok, 2002, Cancer research.

Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells.

S. Mok, G. Yiu, S. Ho, 2001, Cancer research.

Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes

S. Mok, Suet-Ying Kwan, K. Lu, 2021, Journal of experimental & clinical cancer research : CR.

R. Berkowitz, S. Mok, W. Welch, 2000, Cancer research.

Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis

S. Mok, M. Deavers, K. Lu, 2011, Cancer Prevention Research.

Low Erythrocyte Complement Receptor Type 1 (CR1, CD35) Expression in Preeclamptic Gestations

S. Mok, Deborah J Anderson, B. Feinberg, 2005, American journal of reproductive immunology.

Clusterin confers paclitaxel resistance in cervical cancer.

S. Mok, D. Park, S. Yeo, 2006, Gynecologic oncology.

p53 gene mutation in human borderline epithelial ovarian tumors.

R. Berkowitz, S. Mok, W. Welch, 1994, Journal of the National Cancer Institute.

Identification of a novel 9 cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum.

R. Berkowitz, S. Mok, W. Welch, 2000, Human pathology.

Immune cell profiling in normal pregnancy, partial and complete molar pregnancy.

R. Berkowitz, S. Mok, M. Callahan, 2007, Gynecologic oncology.

Matrix metalloproteinases and their inhibitors in gestational trophoblastic diseases and normal placenta.

R. Berkowitz, S. Mok, D. Genest, 1999, Gynecologic oncology.

Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors.

R. Berkowitz, S. Mok, D. Bell, 2001, Cancer research.

Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum.

R. Berkowitz, S. Mok, W. Welch, 2000, American journal of clinical pathology.

Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum

R. Berkowitz, S. Mok, W. Welch, 1998, Oncogene.

Selenium binding protein 1 in ovarian cancer

R. Berkowitz, S. Mok, D. Park, 2006, International journal of cancer.

Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade.

G. Rice, S. Mok, M. Quinn, 2002, Carcinogenesis.

Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls.

R. Berkowitz, D. Cramer, S. Mok, 1996, Cancer research.

Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor.

R. Berkowitz, S. Mok, D. Genest, 2000, Gynecologic oncology.

DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases

R. Berkowitz, S. Mok, S. Ng, 1998, Oncogene.

Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma.

S. Mok, K. Choy, J. Kwong, 2005, Neoplasia.

Detailed deletion mapping of chromosome 6q in borderline epithelial ovarian tumors.

R. Berkowitz, S. Mok, W. Welch, 1995, Cancer research.

Understanding the pathogenesis of primary peritoneal carcinoma: involvement of the BRCA1 and p53 genes.

S. Mok, J. Schorge, 1999, Human pathology.

A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas.

R. Berkowitz, S. Mok, W. Welch, 1997, Cancer research.

Calcium Dependent FAK/CREB/TNNC1 Signaling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential

M. Birrer, A. Sood, S. Mok, 2014, Nature Communications.

Identification of Biomarkers for Clear Cell Ovarian Adenocarcinoma

M. Birrer, S. Mok, H. Tsuda, 2010 .

Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array

Yang Li, Samuel C. Mok, Zugen Chen, 2004, Human Genetics.

Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.

R. Berkowitz, S. Mok, K. Wong, 2005, Gynecologic oncology.

Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review

S. Skates, D. Cramer, B. Ye, 2004, Disease markers.

Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: Identification and characterization using proteomic profiling and mass spectrometry

S. Gygi, R. Berkowitz, S. Skates, 2003 .

Blood and urine markers for ovarian cancer : A comprehensive review 1

S. Skates, D. Cramer, B. Ye, 2014 .

Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells

Shuk-Mei Ho, Samuel C. Mok, S. Mok, 1999 .

Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells.

R. Berkowitz, B. Ye, S. Mok, 2003, Gynecologic oncology.

Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine

R. Berkowitz, S. Skates, Dale Edwards, 2006, Clinical Cancer Research.

Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.

A. Sood, S. Mok, Jinsong Liu, 2011, Neoplasia.

Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of

A. Sood, S. Mok, Jinsong Liu, 2011 .

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

N. Hacker, M. Birrer, S. Mok, 2015, Oncotarget.

TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Jinsong Liu, M. Birrer, S. Mok, 2013, Cancer research.

c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.

R. Berkowitz, S. Mok, D. Genest, 1998, The Journal of reproductive medicine.

Potential markers that complement expression of CA125 in epithelial ovarian cancer.

Yinhua Yu, Jinsong Liu, R. Bast, 2005, Gynecologic oncology.

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Christopher P Crum, R. Drapkin, S. Mok, 2005, Cancer research.

Pathogenesis and Clinical Management of Uterine Serous Carcinoma

S. Mok, K. Wong, Suet-Ying Kwan, 2020, Cancers.

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.

Ross S Berkowitz, Ke Hao, R. Berkowitz, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PAX2 Expression in Ovarian Cancer

Samuel C. Mok, S. Mok, K. Wong, 2013, International journal of molecular sciences.

BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome

C. Deng, R. Greenberg, D. Livingston, 2002, Cell.

Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women

S. Mok, M. Birrer, V. Wang, 2009, International journal of cancer.

Gene expression, immunolocalization, and secretion of human defensin-5 in human female reproductive tract.

S. Mok, A. Quayle, Y. M. Wang, 1998, The American journal of pathology.

Biomarker discovery in epithelial ovarian cancer by genomic approaches.

S. Mok, T. Bonome, K. Wong, 2007, Advances in cancer research.

Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas

R. Berkowitz, S. Mok, Michael E. Johnson, 2005, Clinical Cancer Research.

Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy

H. Friess, J. Kleeff, M. Büchler, 2002, Diseases of the colon and rectum.

Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.

R. Berkowitz, S. Mok, M. Muto, 2001, Cancer research.

Aberrant Promoter Methylation of Sparc in Ovarian Cancer 1 , 2

S. Mok, J. Kwong, N. Said, 2014 .

Aberrant promoter methylation of SPARC in ovarian cancer.

S. Mok, J. Kwong, N. Said, 2009, Neoplasia.

Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors

C. Mathew, S. Mok, A. D’Andrea, 2003, Nature Medicine.

Mesothelial‐to‐mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer

J. Jimenez-Heffernan, S. Mok, M. López-Cabrera, 2017, The Journal of pathology.

Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays.

N. Rao, Zugen Chen, S. Mok, 2005, Cancer genetics and cytogenetics.

Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes

John Quackenbush, R. Berkowitz, S. Mok, 2013, PloS one.

Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1

Yong Li, Kenny Kwan, S. Mok, 2016, Nature Communications.

Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo.

S. Mok, Y. Kwak, Samuel C Mok, 2006, Cancer research.

Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.

W. Wong, R. Berkowitz, M. Birrer, 2004, Cancer genetics and cytogenetics.

Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors

R. Berkowitz, S. Mok, W. Welch, 1999, Oncogene.

A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas

R. Berkowitz, S. Mok, W. Welch, 1998, Oncogene.

Poor survival with wild-type TP53 ovarian cancer?

Anil K Sood, Michael T Deavers, A. Sood, 2013, Gynecologic oncology.

Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.

R. Berkowitz, M. Birrer, S. Mok, 2008, Gynecologic oncology.

SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells.

R. Berkowitz, S. Mok, S. Ng, 2001, The American journal of pathology.

SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells.

R. Berkowitz, S. Mok, K. Wong, 1996, Oncogene.

Molecular cloning of differentially expressed genes in human epithelial ovarian cancer.

R. Berkowitz, R. Knapp, S. Mok, 1994, Gynecologic oncology.

Biomarker Discovery in Ovarian Cancer

S. Mok, K. Wong, C. Tung, 2008, Women's health.

Vascularization and expression of angiogenic factors in partial and complete molar pregnancies.

R. Berkowitz, S. Mok, N. Horowitz, 2008, The Journal of reproductive medicine.

Dysregulation of microRNA‐204 mediates migration and invasion of endometrial cancer by regulating FOXC1

R. Berkowitz, S. Mok, J. Kwong, 2012, International journal of cancer.

Molecular basis of gynecologic diseases

K. Münger, S. Mok, K. Wong, 2020, Essential Concepts in Molecular Pathology.

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Samuel C. Mok, R. Berkowitz, S. Skates, 2004, Clinical Cancer Research.

Osteopontin as an Adjunct to CA 125 in Detecting Recurrent Ovarian Cancer

R. Berkowitz, S. Skates, D. Cramer, 2004 .

Relationship of XIST expression and responses of ovarian cancer to chemotherapy.

Shu-Kay Ng, Edith Heard, Ross S Berkowitz, 2002, Molecular cancer therapeutics.

Overexpression of laminin receptor 1 on decidual cells in partial and complete mole.

R. Berkowitz, S. Mok, M. Callahan, 2008, Gynecologic oncology.

Characterisation of human kallikrein 6/protease M expression in ovarian cancer

R. Berkowitz, S. Mok, S. Ng, 2004 .

A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.

R. Berkowitz, S. Mok, W. Welch, 1996, Oncogene.

Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs).

R. Berkowitz, R. Knapp, J. Fletcher, 1995, Experimental Cell Research.

Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer

R. Berkowitz, S. Mok, Y. Hashiguchi, 2006, Medical oncology.

Analysis of p73 in human borderline and invasive ovarian tumor

R. Berkowitz, S. Mok, S. Ng, 2000, Oncogene.

Microenvironment and Immunology TGF-b Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment

M. Birrer, S. Mok, K. Wong, 2013 .

Multicolor spectral karyotyping of serous ovarian adenocarcinoma

S. Mok, P. Rao, C. Lau, 2002, Genes, chromosomes & cancer.

KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1

S. Mok, K. Wong, Suet-Ying Kwan, 2015, Oncotarget.

Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas

S. Scherer, L. Tsui, R. Berkowitz, 1997, Oncogene.

Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers

D. Bowtell, D. Huntsman, Dianne Miller, 2011, PloS one.

Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion

R. Berkowitz, J. Christensen, R. Salgia, 2007, International Journal of Gynecologic Cancer.

DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway

S. Singletary, K. Makino, M. Hung, 2001, Oncogene.

Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum.

R. Berkowitz, S. Mok, W. Welch, 1995, Cancer research.

Differential gene expression pattern between normal human trophoblast and choriocarcinoma cell lines: downregulation of heat shock protein-27 in choriocarcinoma in vitro and in vivo.

R. Berkowitz, S. Mok, S. Ng, 1999, Gynecologic oncology.

Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas

G. Chenevix-Trench, S. Mok, D. Purdie, 2001, British Journal of Cancer.

Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment

Stephen T. C. Wong, Fuhai Li, S. Mok, 2016, Biomolecules.

Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance

W. Woodward, S. Mok, R. Broaddus, 2013, PloS one.

Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer

M. Birrer, S. Mok, V. Vathipadiekal, 2012, PloS one.

S 1 P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells

S. Mok, Gong Yang, Jinsong Liu, 2008 .

Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision

S. Mok, K. Lu, A. Klimczak, 2018, Cancers.

Signaling in Ovarian Cancer β Factor-That Contribute to the Inhibition of Transforming Growth Expression Profiling Identifies Altered Expression of Genes

M. Birrer, S. Mok, T. Bonome, 2006 .

PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas

S. Mok, K. Wong, A. Malpica, 2009, Modern Pathology.

Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells

S. Mok, S. Ho, V. Syed, 2003, Oncogene.

Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin.

Chun-Min Lo, Ross S Berkowitz, R. Berkowitz, 2007, Neoplasia.

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

S. Mok, S. Ho, S C Mok, 1999, Proceedings of the National Academy of Sciences of the United States of America.

The biology of ovarian cancer.

S. Mok, N. Auersperg, S. Johnson, 1998, Seminars in oncology.

Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers

Gabriela Chiosis, Hatice U. Osmanbeyoglu, Petar Jelinic, 2018, Nature Communications.

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.

R. Berkowitz, S. Mok, W. Welch, 2007, Gynecologic oncology.

Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies.

A. Jazaeri, J. Boyd, M. Birrer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.

Steven J Skates, Ross S Berkowitz, R. Berkowitz, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Classification of ovarian cancer: a genomic analysis.

R. Berkowitz, J. Boyd, M. Birrer, 2008, Advances in experimental medicine and biology.

Prostate carcinoma tissue proteomics for biomarker discovery

J. Richie, B. Ye, S. Mok, 2003, Cancer.

Loss of LKB1 in high‐grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53

S. Mok, J. Celestino, Suet-Ying Kwan, 2014, Cancer.

New technologies for the identification of markers for early detection of ovarian cancer

B. Ye, S. Mok, C. Bandera, 2003, Current opinion in obstetrics & gynecology.

Antiproliferative and teratogenic activities of the bishemisuccinates of 7α-hydroxycholesterol and 7β-hydroxycholesterol

S. Mok, H. Yeung, W. Chan, 1994 .

Frequent microsatellite instability in epithelial borderline ovarian tumors.

R. Berkowitz, S. Mok, W. Welch, 1996, Cancer research.

Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance

R. Berkowitz, S. Mok, T. Bonome, 2006, Clinical Cancer Research.

Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients

B. Ye, S. Mok, W. Welch, 2008, Clinical Cancer Research.

Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters

S. Mok, Han Liang, R. Broaddus, 2017, Clinical Cancer Research.

Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype

S. Mok, Suet-Ying Kwan, K. Lu, 2020, Cancers.

A Novel Protease Homolog Differentially Expressed in Breast and Ovarian Cancer

S. Mok, A. Anisowicz, R. Sager, 1996, Molecular medicine.

Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses

R. Berkowitz, S. Mok, K. Wong, 2005, Clinical Cancer Research.

Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.

R. Berkowitz, R. Knapp, S. Mok, 1993, Cancer research.

Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression

S. Mok, K. Wong, Suet-Ying Kwan, 2020, Cancers.

Chromatofocusing fractionation and two‐dimensional difference gel electrophoresis for low abundance serum proteins

J. Richie, S. Mok, M. O'Leary, 2005, Proteomics.

Differential hRad17 expression by histologic subtype of ovarian cancer

R. Berkowitz, S. Mok, W. Welch, 2011, Journal of ovarian research.

Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer

R. Berkowitz, M. Birrer, S. Mok, 2008, Clinical Cancer Research.

S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells

S. Mok, Gong Yang, Jinsong Liu, 2008, Molecular Cancer Therapeutics.

ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment

Stephen T. C. Wong, J. Sheng, S. Mok, 2020, Nature Communications.

Recent technical strategies to identify diagnostic biomarkers for ovarian cancer

B. Ye, S. Mok, Audrey Gagnon, 2007, Expert review of proteomics.

Increased HLA-DMBExpression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer

R. Berkowitz, M. Birrer, S. Mok, 2008 .

1 Identification of FGFR 4 as a Potential Therapeutic Target for Advanced-Stage High-Grade Serous Ovarian Cancer

M. Birrer, A. Sood, S. Mok, 2012 .

Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.

S. Gygi, R. Berkowitz, S. Skates, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular mechanisms underlying SHP-1 gene expression.

Alberto Martin, S. Mok, H. Tsui, 2002, European journal of biochemistry.

ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression

M. Birrer, S. Mok, K. Wong, 2018, Cancers.

Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.

R. Berkowitz, S. Mok, W. Welch, 2000, Gynecologic oncology.

CAF reprogramming inhibits ovarian cancer progression

S. Mok, Cecilia S. Leung, T. Yeung, 2014, Cell cycle.

Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer

M. Birrer, A. Sood, S. Mok, 2013, Clinical Cancer Research.

Corresponding Autoantibodies in Ovarian Cancer Patients Relevant Tumor-Associated Antigens and Their Use of a Combination of Approaches to Identify and Validate

S. Mok, W. Welch, J. Schorge, 2008 .

C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin

R. Berkowitz, S. Mok, W. Welch, 2010, Clinical Cancer Research.

Novel anti‐filamin‐A antibody detects a secreted variant of filamin‐A in plasma from patients with breast carcinoma and high‐grade astrocytoma

Koichi Nagasaki, M. Raffeld, L. Harris, 2009, Cancer science.

Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array.

Zugen Chen, S. Mok, Cheng Li, 2004, Cancer genetics and cytogenetics.

Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells.

R. Berkowitz, M. Birrer, S. Mok, 2009, Neoplasia.

Dynamic expression of Dab2 in the mouse embryonic central nervous system

S. Mok, W. Chan, K. Cheung, 2008, BMC Developmental Biology.

Dynamic expression of Dab 2 in the mouse embryonic central nervous system

S. Mok, W. Chan, K. Cheung, 2008 .

A new human topoisomerase III that interacts with SGS1 protein.

R. Berkowitz, S. Mok, S. Ng, 1999, Nucleic acids research.

Expression of human estrogen receptor-a and -b, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells (mutationysequence deletionyestrogen actionyandrogen actionyprogesterone action)

S. Mok, S. Ho, E. Jensen, 1999 .

Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

B. Monk, R. Burger, K. Nephew, 2021, Journal of the National Cancer Institute.

The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer

Michael J. Birrer, Anais Malpica, Karen H. Lu, 2011, The American journal of surgical pathology.

SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment

Stephen T. C. Wong, A. Jazaeri, J. Sheng, 2021, Cancers.

FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.

E. Oliva, M. Birrer, S. Mok, 2013, The Journal of clinical investigation.

Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic analysis of ovarian cancer

Jie Peng, S. Mok, Pei Wang, 2021, bioRxiv.

Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.

R. Berkowitz, S. Mok, W. Welch, 1998, Cancer research.

Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target

G. Chenevix-Trench, K. Khanna, S. Mok, 1999, Oncogene.

Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system.

S. Mok, K. Wong, R. Cheng, 2001, BioTechniques.

Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines.

S. Mok, C. Bandera, H. Tsui, 2003, Anticancer research.

Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.

Ross S Berkowitz, R. Berkowitz, M. Birrer, 2010, Gynecologic oncology.

Cancer Therapy : Preclinical C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN 4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin

R. Berkowitz, S. Mok, W. Welch, 2011 .

Biomarkers of Mucinous Tumors of the Ovary

S. Mok, Michael E. Johnson, L. Ozbun, 2007, Disease markers.

Expression of Dab2, a Tumor Suppressor, in the Human Fetal Hippocampus and Neocortex

S. Mok, W. Chan, Hui Zhao, 2008, Neuroembryology and Aging.

Multiple Diseases Discriminated by Quantitation of Blood Transcriptome

S. Mok, K. Marshall, C. Liew, 2009 .

Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.

K. Nephew, G. Fulci, D. Cella, 2023, Gynecologic oncology.

Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.

M. Birrer, S. Mok, K. Wong, 2008, Neoplasia.

Immune cell profiling in intraplacental and postmolar choriocarcinomas.

R. Berkowitz, S. Mok, M. Callahan, 2008, The Journal of reproductive medicine.

An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer

Stephen T. C. Wong, Ying Zhu, Jianting Sheng, 2019, 2019 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI).

Advances in Brief A Novel 4-cM MinimallyDeletedRegionon ChromosomellplS . l Associatedwith High Grade Nonmucmous Epithelial Ovarian Carcinomas 1

R. Berkowitz, S. Mok, W. Welch, 2006 .

Molecular biology of gestational trophoblastic neoplasia: a review.

R. Berkowitz, S. Mok, V. Fulop, 2004, The Journal of reproductive medicine.

DNA copy number abnormality of oral squamous cell carcinoma detected with cDNA array-based comparative genomic hybridization.

S. Mok, M. Birrer, R. Jordan, 2004, Cancer genetics and cytogenetics.

Disabled-2: a positive regulator of the early differentiation of myoblasts

S. Mok, W. Chan, Tin-Lap Lee, 2020, Cell and Tissue Research.

Product Application Focu s Identification of Differentially Expressed Gene s from Ovarian Cancer Cells by MICROMAX™ cDNA Microarray System

S. Mok, K. Wong, R. Cheng, 2001 .

Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature

A. Jazaeri, S. Mok, P. Hwu, 2019, Cancer Immunology, Immunotherapy.

Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens.

Prahlad T. Ram, K. Baggerly, P. Ram, 2017, JCI insight.

Microfibril-associated protein 5 and the regulation of skin scar formation

S. Mok, T. Koh, Trevor R Leonardo, 2023, Scientific reports.

Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis

S. Mok, G. Samimi, E. Colvin, 2017, Scientific Reports.

Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.

J. Sheng, S. Mok, K. Wong, 2023, Cancer research.

Characterisation of human kallikrein 6/protease M expression in ovarian cancer

S. Mok, S. Ng, S. Ng, 2004, British Journal of Cancer.

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer

Jeffrey R. Whiteaker, Sara R. Savage, Uliana J. Voytovich, 2023, Cell.

Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer.

R. Berkowitz, S. Mok, T. Kwok, 1995, Gynecologic oncology.

Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix.

S. Mok, C. S. Chan, V. Wang, 2004, Cancer letters.

Amendment history : Expression of Concern ( June 2018 ) Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens

Prahlad T. Ram, K. Baggerly, Y. Wang, 2018 .

Dynamic Expression of Dab2 in the Mouse Embryonic Central Nervous System Journal Article Bmc Developmental Biology Dynamic Expression of Dab2 in the Mouse Embryonic Central Nervous System

S. Mok, K. Cheung, P. Rezaie, 2022 .

FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.

E. Oliva, M. Birrer, S. Mok, 2013, The Journal of clinical investigation.

Disabled-2: a positive regulator of the early differentiation of myoblasts

S. Mok, Tin-Lap Lee, Hui Zhao, 2020, Cell and Tissue Research.

Recent advances in molecular biology of gestational trophoblastic diseases. A review.

R. Berkowitz, S. Mok, I. Gáti, 2002, The Journal of reproductive medicine.

C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin

R. Berkowitz, S. Mok, W. Welch, 2010, Clinical Cancer Research.

Dynamic Expression of Dab2 in the Mouse Embryonic Central Nervous System Journal Article Bmc Developmental Biology Dynamic Expression of Dab2 in the Mouse Embryonic Central Nervous System

S. Mok, K. Cheung, P. Rezaie, 2022 .

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low‐grade serous carcinoma

S. Mok, K. Wong, A. Malpica, 2013, The Journal of pathology.

Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement.

S. Mok, C. Lo, K. Yip, 2016, American journal of physiology. Cell physiology.

BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum

R. Berkowitz, S. Mok, M. Muto, 1998, Obstetrics and gynecology.

The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer

M. Birrer, S. Mok, K. Wong, 2011, The American journal of surgical pathology.

Whole-genome allelotyping using laser microdissected tissue.

S. Mok, C. Feltmate, 2005, Methods in molecular biology.

Frequent microsatellite instability in epithelial borderline ovarian tumors.

S. Mok, W. Welch, M. Muto, 1996, Cancer research.